Back to search results

Patient-driven Blood Pressure Management for Chronic Kidney Disease

This study is looking at whether patients with chronic kidney disease (CKD) can effectively manage their own blood pressure (BP) medications with guidance from a clinical pharmacist. You would learn how to monitor your home BP and adjust your medications based on a set plan. This approach is being compared to standard care, where doctors typically adjust medications, and also to just monitoring your home BP and contacting your doctor if it's high. The study aims to see if this patient-driven method works better to lower BP. We are looking for adults aged 18 or older with CKD stages 2, 3, or 4 and uncontrolled high blood pressure. The main goal is to see the change in your office blood pressure after 12 months. The study plans to enroll 160 participants, but the current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific interventions. It plans to enroll 160 participants.
What's involved
You would be educated on how to monitor your home blood pressure and how to adjust your medications. You would then monitor your blood pressure and make adjustments under the guidance of a clinical pharmacist.
Compensation
Not stated in the trial record.
Follow-up
Your office blood pressure will be measured at 12 months to assess the main outcome.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05546099

Patient-driven Management of BP in CKD

Recruiting
PHASE3Ages 18+InterventionalTreatment
VA Office of Research and Development
~160 participants
Updated 2025-10-30 on ClinicalTrials.gov
What's tested:Self-management of BP medicationsSelf-monitoring of home BP

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in standardized office BP
Measured over 12 months

Conditions

Chronic Kidney Disease

Explore related trials

Chronic Kidney DiseaseHypertension

NCT05546099

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Iowa City VA Health Care System, Iowa City, IA

    Iowa City, Iowastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Diana Jalal, MD · PRINCIPAL_INVESTIGATOR · Iowa City VA Health Care System, Iowa City, IA

Who to contact

Diana Jalal, MD
[email protected]
(319) 338-0581 · ext. 635214
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 18 years,
CKD stage 3 or 4 (estimated GFR: 15-59 mL/min/1.73m2) or
Stage 2 CKD (estimated GFR 60-89 mL/min/1.73m2) with urinary albumin/creatinine ratio (ACR 300 mg/g if no DM and 30 mg/g if with DM), and
Uncontrolled hypertension defined as the avg of 2 readings \> 140 systolic.

Exclusion

Severely uncontrolled hypertension defined as systolic BP \>180,
Patients with resistant hypertension and taking 4 BP medications,
Orthostatic hypotension defined as reduced systolic BP by 20 mmHg or diastolic BP by 10 mmHg after 3 minutes of standing,
Severe CKD defined as estimated GFR \< 20 mL/min/1.73m2,
Life expectancy \<1 year,
Severe liver disease,
Severe congestive heart failure,
Severe cognitive decline due to dementia,
Pregnant, breastfeeding, or unwilling to use adequate birth control

What this trial measures

  • Change in standardized office BP12 months

    Detailed procedure for standardized office BP measurement: This will be obtained by a trained research coordinator in accordance with the ACC/AHA and KDIGO (Kidney Disease Improving Global Outcomes) guideline.